



brainstorm
cell therapeutics

BrainStorm Cell Therapeutics

NASDAQ: BCLI

Chaim Lebovits CEO
Cell & Gene Therapy Investor
Day

Forward Looking Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at <http://www.sec.gov>.

These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.


2017-2018 Company Progress

Manufacturing Technology Excellence

- Advanced autologous cell therapy platform
- NurOwn Cryopreservation

Non-Dilutive Grants

- California Institute for Regenerative Medicine (CIRM)
- Israel Innovation Authority




Strong Clinical and Basic Science


- Phase 3 ALS study enrolling at 6 US sites
- Broad CNS preclinical pipeline
- 2 AAN platform presentations April 2018

Patient Focus


- Patient Advocacy Leadership
- Expanded phase 3 study to include Canadian ALS patients



NurOwn[®] ALS Development




Enhanced NTF Production MSC-NTF Cells



Responder Analysis ≥ 1.5 point/month improvement

All participants (n=46)

Rapid Progressors (n=21)



* $p < 0.05$ (two-sided Fisher's exact test)

26

48

200

Phase 1/2

Phase 2

Phase 3

Company Leadership Capabilities Strengthened

Management Team

- Chaim Lebovits, CEO
- Ralph Kern MD, COO and CMO
- Uri Yablonka, Chief Business Officer
- Eyal Rubin, CFO
- Mary Kay Turner, VP Government Affairs and Patient Advocacy
- Yael Gothelf PhD, VP Scientific and Regulatory Affairs
- Revital Aricha PhD, VP R&D
- Yossef Levy PhD, VP Cell Production

Board of Directors- recent additions

- Arturo Arraya MA, BS, MBA, formerly Vice President and Head of Global Commercial for Novartis' Cell and Gene Therapies Unit
- June S. Almenoff MD PhD, formerly President and CMO of Furiex Pharmaceuticals. Chief Operating Officer & Chief Medical Officer of Innovate Biopharmaceutical
- Tony Polverino PhD, CSO Kite Pharmaceuticals

Scientific Advisory Board

- Jerold Chun MD PhD, Neuroscientist and Professor at Sanford Burnham Prebys Medical Discovery Institute
- Stanley Appel MD, ALS leader and Professor Houston Methodist Hospital and Professor of Neurology at Weill Medical College of Cornell University
- Amit Bar-Or MD FRCP, Neuroimmunologist and MS leader, Professor of Neurology at UPenn/CHOP



brainstorm
cell therapeutics

BrainStorm Cell Therapeutics

NASDAQ: BCLI

Thank You